Article
Oncology
Beatriz Rey-Bua, Monica Cabrero, Leyre Bento, Juan Montoro, Mariana Bastos-Oreiro, Rocio Parody, Lucrecia Yanez, Oriana Lopez-Godino, Joud Zanabili, Pilar Herrera, Gonzalo Gutierrez, Ariadna Perez, Jose L. Pinana, Silvana Novelli, Maria Cortes, Ana Maria Sureda, Dolores Caballero, Alejandro Martin Garcia-Sancho
Summary: Follicular lymphoma (FL) is a common subtype of indolent lymphoma, and there is a risk of transformation into aggressive lymphoma. Allogeneic hematopoietic stem cell transplantation (alloSCT) could be a potentially curative option for transformed FL, but more research is needed to fully understand its efficacy and toxicity.
Review
Immunology
Erinn Zixuan Sim, Nobuaki Shiraki, Shoen Kume
Summary: Recent advancements in differentiating PSCs into pancreatic islet cells have led to the discovery of novel signaling pathways and molecules, with potential therapeutic applications demonstrated through cell transplantation studies. Single-cell transcriptomics and metabolomics have provided valuable insights into endocrine cell growth and pancreatic development.
INFLAMMATION AND REGENERATION
(2021)
Review
Rheumatology
Dinesh Khanna, Nancy Krieger, Keith M. Sullivan
Summary: This narrative review examines the evolving cell therapies for the treatment of diffuse cutaneous scleroderma (dcSSc) and other autoimmune diseases, including mesenchymal stem cells, chimeric antigen receptor-based therapy, tolerogenic dendritic cells, and facilitating cells.
Review
Oncology
Khodr Terro, Layal Sharrouf, Jean El Cheikh
Summary: Extranodal Natural Killer/T-cell lymphoma (ENKTL) is an extremely rare and highly lethal type of lymphoma. It mainly manifests as necrotic granulomatous lesions in the midline area. There are two subtypes of ENKTL, with the nasal subtype being the most common and the other subtype affecting rarer sites. ENKTL is known for its expression of multidrug resistance-associated P-glycoprotein, making it difficult to treat. Radiotherapy combined with chemotherapy is recommended for localized ENKTL, while hematopoietic stem cell transplantation (HSCT) may be considered for advanced and relapsed cases.
FRONTIERS IN ONCOLOGY
(2022)
Article
Hematology
Robert Puckrin, Neil Chua, Kelly Chin, Anthea Peters, Peter Duggan, Mona Shafey, Jan Storek, Kareem Jamani, Carolyn Owen, Douglas Stewart
Summary: ASCT demonstrates high rates of durable remission in relapsed FL, with long-term follow-up revealing that more than 50% of transplanted patients may be functionally cured of their lymphoma. The optimal timing to consider ASCT is at first or second relapse, regardless of POD24 status.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Chun-Hui Lee, Tzu-Chien Lin, Ming Yao, Liang-Tsai Hsiao, Bor-Sheng Ko, Chia-Jen Liu, Tsai-Yun Chen
Summary: This study analyzed the long-term follow-up data of patients who underwent allo-HSCT in Taiwan and found that allo-HSCT could be a salvage therapeutic option for relapsed or refractory B-cell lymphoma. Complete remission at the time of allo-HSCT and the presence of GVHD were independent variables for overall survival.
Review
Oncology
Miriam Marangon, Carlo Visco, Anna Maria Barbui, Annalisa Chiappella, Alberto Fabbri, Simone Ferrero, Sara Galimberti, Stefano Luminari, Gerardo Musuraca, Alessandro Re, Vittorio Ruggero Zilioli, Marco Ladetto
Summary: Mantle Cell Lymphoma (MCL) is a rare lymphoproliferative disorder that has been regarded as incurable since its identification. For two decades, allogeneic transplantation has been the only option capable of ensuring prolonged remissions and potential cure. However, its application has been limited by feasibility constraints and significant toxicity, particularly in elderly patients.
Article
Medicine, General & Internal
Chunmeng Rong, Lixia Sheng, An Wu, Ye Sun, Guifang Ouyang
Summary: There is currently no established standard guideline for the treatment of plasmablastic lymphoma (PBL), which has a poor prognosis due to early relapse after chemotherapy. This case study presented a 52-year-old HIV-negative man with PBL who achieved complete remission after induction therapy but relapsed after autologous hematopoietic stem cell transplantation. Following salvage allogeneic hematopoietic stem cell transplantation, the patient achieved remission again and has been disease-free for over 4 years. Further clinical studies are needed to explore the role of allogeneic hematopoietic stem cell transplantation in refractory and recurrent PBL.
Article
Health Care Sciences & Services
Taha Al-Juhaishi, Azra Borogovac, Sami Ibrahimi, Matthew Wieduwilt, Sairah Ahmed
Summary: Hodgkin's lymphoma is a rare but curable disease, with high success rates using modern chemotherapy regimens. For patients who do not respond or relapse after initial treatments, high-dose chemotherapy and autologous hematopoietic stem cell transplantation can provide a cure. For patients who relapse after autologous transplant or have chemorefractory disease, allogeneic hematopoietic stem cell transplantation is a proven curative therapy. Newer agents such as brentuximab vedotin and immune checkpoint inhibitors can also be considered to increase the number of patients eligible for transplantation.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Oncology
A. Kopinska, A. Koclega, A. Wieczorkiewicz-Kabut, K. Wozniczka, D. Kata, M. Wlodarczyk, G. Helbig
Summary: Refractory and relapsed Hodgkin lymphoma patients who underwent allogeneic stem cell transplantation showed a 2-year overall survival of 40%. Chemosensitive disease at transplant entry was associated with better outcomes, despite some patients developing graft-versus-host disease. Allo-SCT remains a potential curative approach for long-term survival in this high-risk patient population.
PATHOLOGY & ONCOLOGY RESEARCH
(2021)
Review
Oncology
Xinsheng Liu, Yaxin Zheng, Hongtao Li, Meiyi Wang, M. James You, Chen Tian
Summary: The effect of autologous hematopoietic stem cell transplantation (auto-HSCT) versus conventional chemotherapy or allogeneic hematopoietic stem cell transplantation (allo-HSCT) on the survival of patients with advanced follicular lymphoma (FL) is uncertain. This study included 13 studies and found that auto-HSCT improved overall survival (OS), progression-free survival (PFS), and event-free survival (EFS) compared with conventional chemotherapy. In addition, auto-HSCT resulted in longer OS and lower non-relapse mortality (NRM) compared with allo-HSCT.
Review
Medicine, General & Internal
Luca Castagna, Roberto Bono, Stefania Tringali, Giuseppe Sapienza, Alessandra Santoro, Alessandro Indovina, Vittoria Tarantino, Laura Di Noto, Aurelio Maggio, Caterina Patti
Summary: This paper analyzes the results of ALLO-SCT and CAR-T-cell therapy in patients with aggressive lymphomas and identifies the ideal scenarios for each treatment.
FRONTIERS IN MEDICINE
(2022)
Review
Cell & Tissue Engineering
Zheng-Li Xu, Xiao-Jun Huang
Summary: Allogeneic hematopoietic stem cell transplantation is widely used in treating hematological diseases, with optimized grafts being crucial for improving outcomes. However, there is currently no uniform standard for optimized grafts in transplantation. Future research may focus on identifying the cellular elements responsible for the effects of allo-HSCT.
STEM CELLS TRANSLATIONAL MEDICINE
(2021)
Review
Oncology
Christine Greil, Monika Engelhardt, Juergen Finke, Ralph Waesch
Summary: Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a controversial treatment for multiple myeloma (MM) due to its associated toxicity. However, recent data suggests that it should be considered in young patients without comorbidities, particularly in high-risk cases as part of a tandem approach. Prospective studies, especially those involving new immunotherapeutic approaches, are needed to further evaluate its efficacy.
Review
Medicine, General & Internal
David A. Bond, Peter Martin, Kami J. Maddocks
Summary: The increasing number of approved therapies for relapsed mantle cell lymphoma (MCL) provides patients with effective treatment options, but also increases the complexity in prioritization and sequencing of these therapies. Various options including chemo-immunotherapy, BTK inhibitors, Lenalidomide, bortezomib, Venetoclax, and CAR-T therapies are available for relapsed MCL, each with their own toxicity profiles, mechanisms of action and efficacy. Future directions in research include exploring combination treatment strategies and new therapies.
JOURNAL OF CLINICAL MEDICINE
(2021)